China
Africa
Explore chapters and articles related to this topic
Medicinal Plants for Eczema
Published in Namrita Lall, Medicinal Plants for Cosmetics, Health and Diseases, 2022
Trichilia emetica Vahl. (Figure 5.4), commonly known as Natal mahogany, is part of the Meliaceae family that is mainly located within tropical and subtropical regions; however, it has been seen within the savanna region (Lall and Kishore, 2014; Diallo et al., 2003). This widespread small tree is used throughout Africa for its medicinal uses (Diallo et al., 2003; Komane, Olivier, and Viljoen, 2011).
Antiprotozoal Effects of Wild Plants
Published in Mahendra Rai, Shandesh Bhattarai, Chistiane M. Feitosa, Ethnopharmacology of Wild Plants, 2021
Muhammad Subbayyal Akram, Rao Zahid Abbas, José L. Martinez
Trichilia emetica belongs to family Meliaceae and is natively found in the forests of Africa. It is traditionally used for the treatment of abdominal pain, jaundice, skin problems, chest pain and many more (Komane et al. 2015). Atindehou et al. (2004) evaluated 88 plants of Côte d’Ivoire and their 101 crude ethanol extracts to verify antitrypanosomal activity and he founded T. emetica to be the most promising one. The root bark extract shows IC50 value of 0.04 μg/ml against Trypanosoma brucei rhodensiense. Its leaf extracts also exhibited satisfactory results against Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense with IC50value of 14.9 μg/ml and 8.6 μg/ml, respectively (Hoet et al. 2004). Phytochemical analyses reveal the presence of limonoids such as trichilins and seco-liminoids which show antitrypanosomal activity by damaging DNA (Atindehou et al. 2004).
The Disappearance and Substitution of Native Medicinal Species
Published in Mahendra Rai, Shandesh Bhattarai, Chistiane M. Feitosa, Wild Plants, 2020
It is important to remember that the culture of the use of medicinal plants has evolved by itself and with the passage of time, plants that were not of traditional use or species that have similar characteristics to those originally known were incorporated into the pharmacopoeia, replacing one by the other. This happens because the commercialization is carried out by the common names. For example, we can mention that the plant known as “katuava” is used as an energizer and aphrodisiac; various species were identified by this common name, such as Anemopaegma arvense (Bignoniaceae), Psidium cinereum var. paraguariensis (Myrtaceae), Trichilia catigua (Meliaceae), and Erythroxylum vaccinifolium (Erytroxylaceae), all of which are species from different genus and families (Degen et al. 2005).
Natural products for the management of the hepatitis C virus: a biochemical review
Published in Archives of Physiology and Biochemistry, 2020
Walid Hamdy El-Tantawy, Abeer Temraz
Another study was conducted by Galani et al. (2015). The effects of three methanol extracts from Cameroonian medicinal plants: roots of Trichilia dregeana, stems of Detarium microcarpum and leaves of Phragmanthera capitata on HCV infection were investigated. The HCV JFH1 strain cell culture system HCVcc was used. The antiviral activity was quantified by immunofluorescent labeling of the HCV E1 envelope protein at 30 h post-infection in the presence of the plant extracts. All extracts showed anti-HCV activity, with half-maximal inhibitory concentrations of 16.16, 1.42, and 13.17 μg/mL, respectively. Huh-7 cells were incubated with the extracts for 72 h, and the T. dregeana extract was not toxic at concentrations up to 200 μg/mL, D. microcarpum was not toxic at concentrations up to 100 μg/mL and P. capitata was not toxic at concentrations up to 800 μg/mL. All three extracts substantially inhibited HCV entry, but had no effect on replication or secretion. These extracts have distinguished themselves due to their capacity to greatly interfere with the HCV life cycle, principally the entry step. Furthermore, these extracts are not toxic at the active concentration. These three active extracts are HCV entry inhibitors. These inhibitors could be used in combination with other molecules or extracts that inhibit viral replication, such as sofosbuvir or simeprevir. A multi-drug therapy targeting the different steps of the virus life cycle might overcome the development of virus resistant mutants (Galani et al.2015).